Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors

Cancer

Volumn 120, Issue 6, 2014, Pages 864-876

  Yamada, Yuichi ^a   Kohashi, Kenichi ^a   Fushimi, Fumiyoshi ^b   Takahashi, Yusuke ^a   Setsu, Nokitaka ^a   Endo, Makoto ^a   Yamamoto, Hidetaka ^a   Tokunaga, Shoji ^c   Iwamoto, Yukihide ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASO IIZUKA HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Akt; hemangiopericytoma; mammalian target of rapamycin (mTOR); receptor tyrosine kinase; solitary fibrous tumor

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR BETA; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; S6 KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEGENERATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NECROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLITARY FIBROUS TUMOR; VERY ELDERLY; WESTERN BLOTTING;

AKT; HEMANGIOPERICYTOMA; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); RECEPTOR TYROSINE KINASE; SOLITARY FIBROUS TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NECROSIS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RIBOSOMAL PROTEIN S6; SOLITARY FIBROUS TUMORS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84896703916     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28506     Document Type: Article

References (40)

1. De Pas T, Toffalorio F, Colombo P, et al. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol. (2008); 3: 938-941.
2. Prunotto M, Bosco M, Daniele L, et al. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer. (2009); 64: 244-246.
3. Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR,. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol. (2010); 221: 300-307.
4. Sawada N, Ishiwata T, Naito Z, Maeda S, Sugisaki Y, Asano G,. Immunohistochemical localization of endothelial cell markers in solitary fibrous tumor. Pathol Int. (2002); 52: 769-776. (Pubitemid 35478100)
5. Schirosi L, Lantuejoul S, Cavazza A, et al. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am J Surg Pathol. (2008); 32: 1627-1642.
6. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB,. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. (2005); 4: 988-1004.
7. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene. (2005); 24: 7455-7464. (Pubitemid 41637985)
8. Khaleghpour K, Pyronnet S, Gingras AC, Sonenberg N,. Translational homeostasis: eukaryotic translation initiation factor 4E control of 4E-binding protein 1 and p70 S6 kinase activities. Mol Cell Biol. (1999); 19: 4302-4310. (Pubitemid 29242005)
9. Gingras AC, Raught B, Sonenberg N,. Regulation of translation initiation by FRAP/mTOR. Genes Dev. (2001); 15: 807-826. (Pubitemid 32295062)
10. Ruvinsky I, Meyuhas O,. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. (2006); 31: 342-348. (Pubitemid 43903237)
11. Tomita Y, Morooka T, Hoshida Y, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. (2006); 12: 3070-3077. (Pubitemid 43837353)
12. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A,. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. (2009); 22: 1328-1340.
13. Setsu N, Yamamoto H, Kohashi K, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer. (2012); 118: 1637-1648.
14. Endo M, Yamamoto H, Setsu N, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. (2013); 19: 450-461.
15. Fletcher JA, Fletcher CDM, Bridge JA, Lee J-C,. Extrapleural solitary fibrous tumor and haemangiopericytoma. In:, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2013): 80-82.
16. England DM, Hochholzer L, McCarthy MJ,. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. (1989); 13: 640-658. (Pubitemid 19185450)
17. Vallat-Decouvelaere AV, Dry SM, Fletcher CD,. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intrathoracic tumors. Am J Surg Pathol. (1998); 22: 1501-1511. (Pubitemid 28550645)
18. Dormond O, Madsen JC, Briscoe DM,. The effects of mTOR-akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem. (2007); 282: 23679-23686. (Pubitemid 47311969)
19. de Perrot M, Fischer S, Brundler MA, Sekine Y, Keshavjee S,. Solitary fibrous tumors of the pleura. Ann Thorac Surg. (2002); 74: 285-293. (Pubitemid 34734694)
20. Robinson LA,. Solitary fibrous tumor of the pleura. Cancer Control. (2006); 13: 264-269. (Pubitemid 44600937)
21. Fukasawa Y, Takada A, Tateno M, et al. Solitary fibrous tumor of the pleura causing recurrent hypoglycemia by secretion of insulin-like growth factor II. Pathol Int. (1998); 48: 47-52.
22. Guglielmi A, Frameglia M, Iuzzolino P, et al. Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia. J Hepatobiliary Pancreat Surg. (1998); 5: 212-216. (Pubitemid 128662583)
23. Fama F, Le Bouc Y, Barrande G, et al. Solitary fibrous tumour of the liver with IGF-II-related hypoglycaemia. A case report. Langenbecks Arch Surg. (2008); 393: 611-616.
24. Wagner S, Greco F, Hamza A, Hoda RM, Holzhausen HJ, Fornara P,. Retroperitoneal malignant solitary fibrous tumor of the small pelvis causing recurrent hypoglycemia by secretion of insulin-like growth factor 2. Eur Urol. (2009); 55: 739-742.
25. Markman B, Dienstmann R, Tabernero J,. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. (2010); 1: 530-543.
26. Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M,. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol. (2011); 6: 29-39.
27. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. (2004); 25: 2053-2059. (Pubitemid 39534841)
28. Nathan CO, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res. (2004); 10: 5820-5827. (Pubitemid 39180961)
29. Lin HJ, Hsieh FC, Song H, Lin J,. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer. (2005); 93: 1372-1381. (Pubitemid 41752864)
30. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. (2007); 13: 748-753. (Pubitemid 46889749)
31. Matteucci E, Bendinelli P, Desiderio MA,. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis. (2009); 30: 937-945.
32. Brusevold IJ, Soland TM, Khuu C, Christoffersen T, Bryne M,. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci. (2010); 118: 342-349.
33. Asmane I, Watkin E, Alberti L, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. (2012); 48: 3027-3035.
34. Xu AM, Huang PH,. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. (2010); 70: 3857-3860.
35. Malhotra B, Schuetze SM,. Dermatofibrosarcoma protuberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Curr Opin Oncol. (2012); 24: 419-424.
36. Heldin CH,. Autocrine PDGF stimulation in malignancies. Ups J Med Sci. (2012); 117: 83-91.
37. Sierra JR, Tsao MS,. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. (2011); 3 (1 suppl): S21-S35.
38. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. (2008); 68: 10238-10246
39. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. (2013); 45: 131-2.
40. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. (2013); 45: 180-5.